AI-supported mammography screening reduces advanced breast cancer rates and improves early detection, according to the largest randomized controlled trial to date.
Key Details
- 1Over 100,000 Swedish women were randomized to AI-supported vs. standard double-reading mammography screening.
- 2AI-supported screening resulted in a 12% reduction in interval (between-screening) breast cancer diagnoses.
- 316% fewer invasive, 21% fewer large, and 27% fewer aggressive subtype cancers were identified in the AI arm.
- 481% of cancers were detected at screening with AI, versus 74% in the control group—a 9% increase.
- 5False positive rates were similar between groups (1.5% AI, 1.4% control), and radiologist workload was reduced by 44% in interim analyses.
- 6The study supports use of tested AI tools as an aid—not a replacement—for radiologists, especially amid workforce shortages.
Why It Matters
This landmark trial shows substantial clinical benefit and workflow relief from using AI in breast cancer screening, supporting adoption in radiology programs facing growing patient volumes and staff shortages. The findings may shape future screening guidelines and training requirements for imaging AI use.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
•EurekAlert
AI Model Accelerates Accurate Dose Prediction for CyberKnife Radiotherapy
A physics- and spatially informed diffusion model accelerates Monte Carlo–level dose estimation for CyberKnife radiotherapy using planning CT and anatomical data.